drugset
drugset / Trial / NCT03790332

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332 ↗

Phase 1/2 Completed 59 enrolled Pharmacyclics LLC. Janssen Research & Development, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

Timeline

Start
2018-11-19
Primary completion
2025-10-09
Completion
2025-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 420 mg Oral

Indications

chronic graft versus host disease